Oppenheimer raised the firm’s price target on iRhythm (IRTC) to $175 from $130 and keeps an Outperform rating on the shares. The firm notes Q2 revenues were $187M, well ahead of its/consensus $174M estimate. FY25 revenue guide raised to $720M-$730M from $690M-$700M, Oppenheimer adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm price target raised to $190 from $165 at BTIG
- iRhythm price target raised to $180 from $160 at Baird
- iRhythm Technologies: Strong Performance and Growth Potential Justify Buy Rating
- iRhythm price target raised to $170 from $139 at Canaccord
- iRhythm price target raised to $190 from $145 at JPMorgan